Egypts HIV drug market size stood at USD 2.2 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Human immunodeficiency virus (HIV) is a chronic and life-threatening disease, which can be transferred from one person to another through blood-to-blood and sexual contact. It is a virus, which attacks immune cells known as CD-4 cells, making the body susceptible to infections and other diseases.

The overall prevalence of HIV in Egypt remains low as compared to other countries. While the estimated number of people living with HIV in Egypt remains relatively low (11,000 by the end of 2016) compared to the total population, Egypt is reported to have the fastest-growing epidemic in the Middle East and North Africa Region (MENA) by a 76% increase in the number of cases between 2010 and 2016.

This, coupled with the witnessed alarming trend in the number of new confirmed cases by 25-30% annually is seen as worrying signs that point to a dire need for increased investments to avoid further epidemic growth and a failure in controlling the epidemic.



Market Drivers

By the end of 2018, the total number of people living with HIV was estimated to be 16,000 in Egypt, while 1,806 new cases out of about 2300 newly detected in 2018 were introduced to ART in 2018, bringing the total to about 6,500 individuals on treatment, a significant two-fold increase compared 2016. Such a rise in detection, awareness, and treatment will drive up the HIV treatment market in Egypt in the forecast period.

The government with the help of international aids started major screening processes and treatment processes and this will further increase the rate of growth of the HIV treatment market.